ZBIO

Zenas BioPharma, Inc. (ZBIO) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-08-01

Overall Score

Growth Runway

Revenue base remains extremely small at $0.016 per share, limiting scale despite a large market cap.

No recent news indicates a new commercial catalyst or demand inflection.

Profitability

Margins remain deeply negative, with gross margin at -59.7% and net margin at -484.4%.

Returns on capital are still severely negative, with ROIC at -74.7% and ROE at -189.7%.

Financial Strength

Liquidity is strong with a current ratio of 9.9x and cash ratio of 3.0x.

Leverage is manageable, with debt-to-equity at 0.91x and net debt to EBITDA near zero.

Valuation

Valuation remains extremely stretched on sales, with EV/Sales at 2000.1x and P/S at 1972.9x.

Negative free cash flow and negative earnings keep traditional valuation support weak.

Execution Risk

Operating cash flow remains negative and the cash conversion cycle is long at 246 days.

High R&D and SG&A intensity relative to revenue continue to pressure operating leverage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Zenas BioPharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →